Talon Therapeutics, Inc., a biopharmaceutical company, develops and commercializes new and differentiated cancer therapies. Its lead product includes Marqibo (vincristine sulfate liposome injection), which is a novel sphingomyelin/cholesterol liposome encapsulated formulation of vincristine for acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. The company’s product candidates comprise Menadione topical lotion, a novel cancer supportive care product candidate, which is in a Phase II trial for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors in the treatment of cancers; Brakiva (topotecan liposome injection), a...
400 Oyster Point Boulevard
South San Francisco, CA 94080
Founded in 2002
Talon Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013
May 15 13
Talon Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. The company reported a net loss of $17.5 million and deemed dividends attributable to preferred stock of $5.1 million, which when combined, resulted in a net loss applicable to common stockholders of $22.6 million, or $1.03 per basic and diluted share. This compares to a net loss of $30.5 million and deemed dividends of $5.6 million, which when combined, resulted in a net loss applicable to common stockholders of $36.1 million, or $1.66 per basic and diluted share, for the three months ended March 31, 2012. The change in fair value of Talon's preferred stockholders' rights to purchase additional shares of preferred stock contributed to $11.6 million, or $0.53 per share, of the total net loss applicable to common stockholders for the three months ended March 31, 2013. Loss from operations was $4,754,000 against $4,427,000 a year ago. Cash used in operations was $4.8 million for the three months ended March 31, 2013.